1Hoflack G, Maes D, Mateusen B, et al. Efficacy of tilmicosin phosphate in feed for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing - finishing pigs[J]. Journal of Veterinary Medicine B, 2001, 48: 655- 664.
2Chang C F, Yeh T M, Chou C C, etal. Antimicrobial susceptibility and plasmid analysis of Actinobacillus pleuropneumoniae isolated in Taiwan[J]. Veterinary microbiology, 2002, 84: 169-177.
3Denise M, Alexandra R, Sandra L, et al. Antimicrobial re sistanee profile of Actinobacillus pleuropneu moniae and Actinobacillus porcitonsillarum[J]. Veterinary Microbiology, 2007, 122: 146-156.
5Moor G,Basson R, Tonkinson L. Clinical field trails with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocidain swine[J]. Am J Vet Res, 1996, 48: 224- 228.
6Moussa S D, Francois M, Mario J. Postantibiotic and physio logical effects of tilmicosin, tylosin, and apramycin at subminimal and suprainhibitory concentrations on some swine and bovine respiratory tract pathogens[J].International Journal of Antimicrobial Agents, 1999,12 : 229-237.
7Hart FG, KilgoreRW, NutschRG,etal. Efficacy oftulath romycin in the treatment of respiratory disease in pigs caused by Actinobacillus pleuropneumoniae[J].Vet Rec, 2006, 158 (13) : 433.
8Nanjiani I A, Mckelvie J, Benchaoui H A, etal. Evaluation of the therapeutic activity of tulathromycin against swine respiratory disease on farms in Europe[J]. Vet Ther, 2005, 6(2):203- 213.
9George G Z , Daryl J H , Godfrey K M. The postantibiotic effect: a review of in vitro and in vivo data[J]. Ann Pharma cother, 1991, 25:153.
10Novelli A, Mazzei T, Fallani S, et al. In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramyein [J].J Chemother, 1995, 7: 355.
2Eberhard S, Janina S, Monica V, Werner S. Quantitative determination of the macrolide antibiotic tulathromycin in plasma and broncho-alveolar cells of foals using tandem mass spectrometry. Journal of Chromatography B, 2007, 850:464-470.
3Diana G, Scott H, Brian B, James R, Philip I, Chandralal W, Richard P, Schneider, Connie L, Jennifer L, Donald R, Andrew B, Eden E, Robert R,Colman R, Wayne B, Trisha M, David K, Hafid B, Nowakowski M A. An Analytical Method for the Analysis of Tulathromycin, an Equilibrating Triamilide, in Bovine and Porcine Plasma and Lung. Journal of Agricultural And Food Chemistry, 2004, 52:2179-219.
4Venner M, Kerth R, Klug E. Evaluation of tulathromycin in the treatment of pulmonary abscesses in foals. Feterinary Journal, 2007, 174(2): 418-421.
5Washburn K E, Bissett W, Fajt V, Clubb F, Fosgat E G T, Libal M Smyre K E. The safety of tulathromycin administration in goats Journal of Veterinary Pharmacology and Therapeutics, 2007, 30 267-270.
6Clothier K A, Jordan D M, Loynachan A T, Griffith R W. Safety evaluation of tulathromycin use in the caprine species: tulathromycin toxicity assessment in goats. Journal of Veterinary Pharmacology and Therapeutics, 2010, 33: 499-502.
7Godinho K S. Susceptibility testing of tulathromycin: Interpretative breaklints and susceptibility of field isolates. Veterinary Microbiology, 2008, 129(3-4): 426-432.
8Wellman N G, O'Connor A M. Meta-analysis of treatment of cattle with bovine respiratory disease with tulathromycin. Journal of Veterinary Pharmacology and Therapeutics, 2007, 30(3): 234-241.
9Kilgore WR.L Spensley M S, Sun F S, Nutsch R G. Rooney K A, Skogvrboe T L. Therapeutic efficacy of tulathromycin, a novel triamilide antimicrobial, against bovine respiratory disease in feeder calves. Veterinary Therapeutics, 2005, 6(2): 143-153.
10Nanjiani I A, Basano F S, Nazzari R, Toni F, Miotto L. Comparative Efficacy of Tulathromyein vs. FIorfenicol/Flunixin Combination in Bovine Respiratory Disease (BRD) Associated with Mannheimia haemolytiea, Pasteurella multoeida and Histophilus somni, on Italian Commercial Farms. Cattle Practice, 2010, 18: 38-39.
